Questions about this study?
The HopeStage team will email you.
Not recruitingEUCTR 2007-007669-20
A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stabl...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesSchizophrenia
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Belgium · Germany and 2 more locations
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 36
- Sponsor
- Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Belgium, Germany, Slovakia, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2007-007669-20
- Official title
Show the full official title
A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stabl...
Recruitment & locations
Not recruitingBelgium · Germany · Slovakia
1 more locations
- Sweden
Registry details
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
Is this study still recruiting?
The historical registry lists this study as not recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia
A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mai...